Assistant Professor, Medicine, Vanderbilt University School of Medicine
Oncology
Dr. Vicki L. Keedy, MD
Vicki Keedy practices Oncology. She graduated from University of Cincinnati College of Medicine. Dr. Vicki L. Keedy is also a published doctor. She has 23 paper published. The most recent paper is: Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors. Vicki Keedy is registered with Medicare.
Publications
- A randomized phase II study of carboplatin with weekly or every-3-week nanoparticle albumin-bound paclitaxel (abraxane) in patients with extensive-stage small cell lun...
- Enabling a Genetically Informed Approach to Cancer Medicine: A Retrospective Evaluation of the Impact of Comprehensive Tumor Profiling Using a Targeted Next-Generation...
- Phase II Study of Bendamustine in Relapsed Chemotherapy Sensitive or Resistant Small-Cell Lung Cancer.
- Population pharmacokinetics of PEGylated liposomal CPT-11 (IHL-305) in patients with advanced solid tumors.
- Phase I Study of U3-1287, a Fully Human Anti-HER3 Monoclonal Antibody, in Patients with Advanced Solid Tumors.
- Complications of targeted drug therapies for solid malignancies: manifestations and mechanisms.
- Identifying barriers associated with enrollment of patients with lung cancer into clinical trials.
- Composite uterine neoplasm with embryonal rhabdomyosarcoma and primitive neuroectodermal tumor components: rhabdomyosarcoma with divergent differentiation, variant of ...
- American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non-Small-Cell ...
- Synchronous bone marrow metastasis from primary splenic angiosarcoma.
- Prognostic significance of c-Myc expression in soft tissue leiomyosarcoma.
- Prognostic factors for resected non-small cell lung cancer with pN2 status: implications for use of postoperative radiotherapy.
- Does gefitinib shorten lung cancer survival? Chaos redux.
- Adjuvant and neoadjuvant approaches to treat surgically resectable pancreatic cancer.
- Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors.
- Activity of dalotuzumab, a selective anti-IGF1R antibody, in combination with erlotinib in unselected patients with Non-small-cell lung cancer: a phase I/II randomized...
- Adult neuroblastoma complicated by increased intracranial pressure: a case report and review of the literature.
- Phase I study of adenovirus p53 administered by bronchoalveolar lavage in patients with bronchioloalveolar cell lung carcinoma: ECOG 6597.
- Inhibition of angiogenesis in the treatment of non-small cell lung cancer.
- Cyclooxygenase 2 expression in soft tissue leiomyosarcoma.
- Foamy cell angiosarcoma: a rare and deceptively bland variant of cutaneous angiosarcoma.
- Methylthioadenosine phosphorylase and activated insulin-like growth factor-1 receptor/insulin receptor: potential therapeutic targets in chordoma.
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
Vanderbilt University -
University of Cincinnati College of Medicine
Hospital
-
Vanderbilt Hospital and Clinics
Helpful Reviews
Similar Doctors
|
Dr. Jack W. Erter, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Howard A. Burris III, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
Dr. John D. Hainsworth, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. David E. Longacre, MD |
|
|
Dr. Charles E. McKay, MD |